This presentation will identify touchpoints in the diagnosis and drug-development continuum where early/systematic insight into patient perspectives can help accelerate availability of new treatments, differentiate an asset, and add reputational value. Industry, payers, regulators, and investors increasingly seek patient perspective to de-risk their decisions; and patients themselves are keen to partner.
Level of instruction: Basic